GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clarity Pharmaceuticals Ltd (ASX:CU6) » Definitions » Buyback Yield %

Clarity Pharmaceuticals (ASX:CU6) Buyback Yield % : -0.02 (As of May. 05, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Clarity Pharmaceuticals Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Clarity Pharmaceuticals's current buyback yield was -0.02%.


Clarity Pharmaceuticals Buyback Yield % Historical Data

The historical data trend for Clarity Pharmaceuticals's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarity Pharmaceuticals Buyback Yield % Chart

Clarity Pharmaceuticals Annual Data
Trend Jun22 Jun23
Buyback Yield %
-65.78 -0.09

Clarity Pharmaceuticals Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Buyback Yield % Get a 7-Day Free Trial -130.62 -0.49 -0.16 -0.07 -0.09

Competitive Comparison of Clarity Pharmaceuticals's Buyback Yield %

For the Biotechnology subindustry, Clarity Pharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clarity Pharmaceuticals's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clarity Pharmaceuticals's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Clarity Pharmaceuticals's Buyback Yield % falls into.



Clarity Pharmaceuticals Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Clarity Pharmaceuticals's Buyback Yield for the fiscal year that ended in Jun. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-0.013 + 0.183) / 183.0304
=-0.09%

Clarity Pharmaceuticals's annualized Buyback Yield for the quarter that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (-0.004 + 0.121) * 2 / 254.6095
=-0.09%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized semi-annual data, the Repurchase of Stock and Issuance of Stock data used here is two times the semi-annual (Dec. 2023) data.


Clarity Pharmaceuticals Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Clarity Pharmaceuticals's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Clarity Pharmaceuticals (ASX:CU6) Business Description

Traded in Other Exchanges
Address
4 Cornwallis Street, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology.

Clarity Pharmaceuticals (ASX:CU6) Headlines

No Headlines